切换至 "中华医学电子期刊资源库"
高级检索
中华临床实验室管理电子杂志

中华临床实验室管理电子杂志 ›› 2017, Vol. 05 ›› Issue (04) : 217 -220. doi: 10.3877/cma.j.issn.2095-5820.2017.04.005

所属专题： 文献；

专题笔谈

VeriStrat在非小细胞肺癌等肿瘤个体化治疗中的应用现状
陈锋1, 张荣2, 刘昕超2, 崔松2, 杨珺2, 马庆伟2, 陈琛2, 张晓青2, 崔巍1,†()   
  1. 1. 100021　国家癌症中心/中国医学科学院北京协和医学院肿瘤医院检验科
    2. 102206　北京毅新博创生物科技有限公司
  • 收稿日期:2017-09-26 出版日期:2017-11-28
  • 通信作者: 崔巍
  • 基金资助:
    中国医学科学院医学与健康科技创新工程项目(2017-12M-3-005)

Application of VeriStrat test in individualized treatment of non-small cell lung cancer and other tumors

Feng Chen1, Rong Zhang2, Xinchao Liu2, Song Cui2, Jun Yang2, Qingwei Ma2, Chen Chen2, Xiaoqing Zhang2, Wei Cui1,†()   

  1. 1. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    2. Buoying Technologies Inc, Beijing 102206, China
  • Received:2017-09-26 Published:2017-11-28
  • Corresponding author: Wei Cui
  • About author:
    Corresponding author: Cui Wei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

陈锋, 张荣, 刘昕超, 崔松, 杨珺, 马庆伟, 陈琛, 张晓青, 崔巍. VeriStrat在非小细胞肺癌等肿瘤个体化治疗中的应用现状[J]. 中华临床实验室管理电子杂志, 2017, 05(04): 217-220.

Feng Chen, Rong Zhang, Xinchao Liu, Song Cui, Jun Yang, Qingwei Ma, Chen Chen, Xiaoqing Zhang, Wei Cui. Application of VeriStrat test in individualized treatment of non-small cell lung cancer and other tumors[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2017, 05(04): 217-220.

肽谱分(VeriStrat)是一种基于血液蛋白质组学试验，用于非小细胞肺癌(non-small cell lung cancer，NSCLC)患者用药效果的预测性和预后性分类测试方法。该测试时患者被分类为VeriStrat-Good组和VeriStrat-Poor组，通过表征宿主对肿瘤的反应来评估疾病的侵袭性，还可用于NSCLC的精准医学诊断。我们对VeriStrat在临床的应用现状进行阐述，并分析探讨VeriStrat在NSCLC及其他肿瘤个体化治疗中的临床价值，以推动肿瘤个体化治疗的进步。

关键词: 非小细胞肺癌, 个体化治疗, 肿瘤, 肽谱分

The VeriStrat test is a blood-based proteomic test with predictive and prognostic significance in treatment of non-small cell lung cancer (NSCLC). Mass spectra from these patients′ serum samples were classified into two outcome groups, VeriStrat-Good group and VeriStrat-Poor group which are used to evaluate different treatment outcomes. It also cam used for precision medicime of NSCLC. Our paper illustrates the current progress in the clinical application of VeriStrat test, and aims to investigate the clinical value of Veristrat test in the treatment of NSCLC and other tumors. In summary, VeriStrat test is helpful to promote the application of individualized treatments.

Key words: Non-small cell lung cancer, Individualized treatment, Tumors, VeriStrat
1
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016,66(1):7-30.
2
Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture[J]. Eur J Cancer, 2001,37 Suppl 8:S4-66.
3
宋晓燕，李积德，赵君慧. 非小细胞肺癌个体化靶向治疗进展[J]. 医药前沿, 2012(32): 27-28.
4
廉政君，黄建国. 晚期非小细胞肺癌预后相关因素分析[J]. 现代肿瘤医学, 2014,22(1): 95-97.
5
Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study[J]. J Nati Cancer Inst, 2007,99 (11):838-846.
6
Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab[J]. Lung Cancer, 2010,69(3):337-340.
7
Kuiper JL, Lind JS, Groen HJ, et al. VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib[J]. Br J Cancer, 2012,107(11):1820-1825.
8
Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors[J]. J Thorac Oncol, 2012,7(1):40-48.
9
Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non–small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial[J]. J Thorac Oncol, 2012,7(11):1653-1660.
10
Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial[J]. Lancet Oncol, 2014,15(7):713-721.
11
Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non–small cell lung cancer, version 4. 2016[J]. J Nati Compr Canc Netw, 2016,14(3):255-264.
12
Grossi F, Rijavec E, Genova C, et al. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy[J]. Br J Cancer, 2017,116(1):36-43.
13
Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients[J]. Cancer Epidemiol Biomarkers Prev, 2010,19(2):358-365.
14
Mazouni C, Baggerly K, Hawke D, et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure[J]. Proteomics, 2010,10(19):3525-3532.
15
Gautschi O, Dingemans AM, Crowe S, et al. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528[J]. Lung Cancer, 2013,79(1):59-64.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 939-944.
[2] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 844-848.
[3] 钱龙, 陆晓峰, 王行舟, 杜峻峰, 沈晓菲, 管文贤. 神经系统调控胃肠道肿瘤免疫应答研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 86-89.
[4] 曹长青, 郭新艳, 高源, 张存, 唐海利, 樊东, 杨小军, 张松, 赵华栋. 肿瘤微环境参与介导HER2阳性乳腺癌曲妥珠单抗耐药的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 90-95.
[5] 燕速, 霍博文, 徐惠宁. 4K荧光腹腔镜扩大右半结肠CME+D3根治术及No.206、No.204组淋巴结清扫术[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 14-14.
[6] 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 不断提高腹腔镜右半结肠癌D3根治术的规范化[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 1-4.
[7] 杜晓辉, 崔建新. 腹腔镜右半结肠癌D3根治术淋巴结清扫范围与策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 5-8.
[8] 周岩冰, 刘晓东. 腹腔镜右半结肠癌D3根治术消化道吻合重建方式的选择[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 9-13.
[9] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[10] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[11] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[12] 李凤仪, 李若凡, 高旭, 张超凡. 目标导向液体干预对老年胃肠道肿瘤患者术后血流动力学、胃肠功能恢复的影响[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 29-32.
[13] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 徐军, 姬园园, 陈君平, 王健. 伴菊形团结构的脑膜瘤合并颅骨侵犯一例并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(08): 916-919.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号